ATRA
Atara BiotherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The positive interpretation is that the May 7, 2026 FDA meeting update narrowed the path back to a tab-cel BLA resubmission and kept the U.S. opportunity alive after the January 9, 2026 CRL, while the prior March 16, 2026 cost-cut message suggested a much leaner operating base.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.2.
What can break
Going-concern pressure remains material: the March 16, 2026 10-K said year-end 2025 cash was not sufficient to fund planned operations for at least the next 12 months and raised substantial doubt about the company's ability to continue as a going concern [#10-K-2026-03-16].
Momentum
1
Value
57
Sentiment
34
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.00 · Bull $14.00 · Bear $4.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $9.33
Why
Momentum1 · Δ7d -
Value57 · Δ7d +0.2
Sentiment34 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
1
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
57
32% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.3
Sentiment
34
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 1.1 / Value 56.8 / Sentiment 33.9
Fundamentals (TTM)As of 2026-05-29
Fundamentals (TTM)
As of 2026-05-29
Market Cap
$94.7M
Beta
-0.41
Shares Out
7.21M
P/E (TTM)
7.7
P/S (TTM)
0.80
P/FCF (TTM) · Derived
-2.23
Rev YoY
-91.4%
EPS YoY
+89.2%
Gross Margin
+81.6%
Op Margin
+17.3%
Net Debt
-$1.23M
Current Ratio
1.02
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology